Madrigal Pharmaceuticals ... (MDGL)

NASDAQ: MDGL · Real-Time Price · USD

342.84

8.93 (2.67%)

At close: May 01, 2025, 12:09 PM

2.67% (1D)

Bid	339.78
Market Cap	7.57B
Revenue (ttm)	180.13M
Net Income (ttm)	-465.89M
EPS (ttm)	-21.9
PE Ratio (ttm)	-15.65
Forward PE	199.69
Analyst	Buy

Ask	346.6
Volume	339,556
Avg. Volume (20D)	368,262
Open	349.00
Previous Close	333.91
Day's Range	313.19 - 349.00
52-Week Range	200.08 - 377.46
Beta	-0.69

About MDGL

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, ...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 6, 2007

Employees 528

Stock Exchange NASDAQ

Ticker Symbol MDGL

Website https://www.madrigalpharma.com

Full Company Profile

Analyst Forecast

According to 9 analyst ratings, the average rating for MDGL stock is "Buy." The 12-month stock price forecast is $405, which is an increase of 18.13% from the latest price.

Stock Forecasts

Earnings Surprise

New

Madrigal Pharmaceuticals has released their quartely earnings on May 1, 2025:

Revenue of $137.25M exceeds estimates by $23.06M, with Infinity% YoY growth.

EPS of -3.32 exceeds estimates by 0.47, with 55.01% YoY growth.

Next Earnings Release

Madrigal Pharmaceuticals Inc. is scheduled to release its earnings on May 1, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

+14.99%

Madrigal Pharmaceuticals shares are trading higher... Unlock content with Pro Subscription

3 months ago

-10.39%

Madrigal Pharmaceuticals shares are trading lower after the company reported preliminary Q4 and FY24 financial results.

News

Just now · zacks.com

Madrigal (MDGL) Reports Q1 Loss, Tops Revenue Estimates

Madrigal (MDGL) came out with a quarterly loss of $3.32 per share versus the Zacks Consensus Estimate of a loss of $3.62. This compares to loss of $7.38 per share a year ago.

1 month ago · zacks.com

Madrigal (MDGL) Up 0.5% Since Last Earnings Report: Can It Continue?

Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock?

2 months ago · seekingalpha.com

Madrigal Pharmaceuticals: Rezdiffra First-Mover Advantage Gains Traction (Upgrade)

Madrigal Pharmaceuticals, Inc.'s Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity, but GLP-1 competition from Novo and Lilly poses significant future challenges. Madrigal's P...

2 months ago · zacks.com

Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

MDGL stock is rising as it reports better-than-expected fourth-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.

2 months ago · benzinga.com

Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis

On Wednesday, Madrigal Pharmaceuticals, Inc. MDGL reported two-year results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra (resmetirom).

2 months ago · seekingalpha.com

Madrigal Pharmaceuticals Q4 Earnings Review: Strong Quarter, Even Stronger Outlook

Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales up 66% to $103.3m. Despite a net loss of $466m in 2024, Madrigal's cash posi...

2 months ago · fool.com

Why Madrigal Pharmaceuticals Stock Is Soaring Today

Shares of Madrigal Pharmaceuticals (MDGL 16.35%) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday.

2 months ago · seekingalpha.com

Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2024 Earnings Call Transcript

2 months ago · zacks.com

Madrigal (MDGL) Reports Q4 Loss, Tops Revenue Estimates

Madrigal (MDGL) came out with a quarterly loss of $2.71 per share versus the Zacks Consensus Estimate of a loss of $4.12. This compares to loss of $5.68 per share a year ago.